In contrast, DNA-sequencing detected more variants than RNA-seq for MYD88 mutations in this PT-DLBCL cohort (Fig. 2C) and for MYD88 and TP53 variants in our systemic DLBCL cohort (15, 18), which had lower frequencies of bulky tumors and CNVs than this PT-DLBCL cohort. Here, TP53 is linked to diffuse large B-cell lymphoma.